First Patient Dosed: BBP-671 for Propionic Acidemia
Source: Pixabay

First Patient Dosed: BBP-671 for Propionic Acidemia

According to a news release from biopharmaceutical company BridgeBio Pharma, Inc., the first patient was dosed in a Phase 1 study. Researchers are evaluating the safety, tolerability, pharmacodynamics, and pharmacokinetics…

Continue Reading First Patient Dosed: BBP-671 for Propionic Acidemia
New Investigative Therapy for Methylmalonic Acidemia and Propionic Acidemia is Making Regulatory Progress
source: pixabay.com

New Investigative Therapy for Methylmalonic Acidemia and Propionic Acidemia is Making Regulatory Progress

Fast Track Designation and Rare Pediatric Disease Designation have just been awarded from the FDA to HemoShear Therapeutics. This designation was given to their new investigative therapy for propionic acidemia…

Continue Reading New Investigative Therapy for Methylmalonic Acidemia and Propionic Acidemia is Making Regulatory Progress
Company Receives Clearance to Conduct Trial for Propionic and Methylmalonic Acidemia
source: pixabay.com

Company Receives Clearance to Conduct Trial for Propionic and Methylmalonic Acidemia

According to a press release from HemoShear Therapeutics, the company has recently received official clearance from the US Food and Drug Administration (FDA) in regards to its Investigational New Drug…

Continue Reading Company Receives Clearance to Conduct Trial for Propionic and Methylmalonic Acidemia